SCHEMBL18366107

SCHEMBL18366107

CCOC(=O)c1nn(C)c2c1C[C@@H](C(F)(F)F)CC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.46
CCNA2 P20248 4/20 0.36
CDK2 P24941 4/20 0.36
CCNA1 P78396 3/20 0.36
CDK4 P11802 1/20 0.36
CCND3 P30281 1/20 0.36
CDK6 Q00534 1/20 0.36
ELANE P08246 2/20 0.35
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 3/20 0.34
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
MEN1 O00255 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18366102 1.00 RIPK1 (0.46) RIPK1CCNA2CDK2CCNA1CDK4
SCHEMBL19658713 1.00 RIPK1 (0.46) RIPK1CCNA2CDK2CCNA1CDK4
SCHEMBL23278661 0.87 PDE4A (0.37) RIPK1CCNA2CDK2CCNA1ELANE
SCHEMBL18372467 0.87 PDE4A (0.37) RIPK1CCNA2CDK2CCNA1ELANE
SCHEMBL18366103 0.82 RIPK1 (0.50) RIPK1CCNA2CDK2CCNA1ALDH1A1
SCHEMBL18366109 0.82 RIPK1 (0.50) RIPK1CCNA2CDK2CCNA1ALDH1A1
SCHEMBL19659082 0.82 RIPK1 (0.50) RIPK1CCNA2CDK2CCNA1ALDH1A1
SCHEMBL19659085 0.81 RIPK1 (0.49) RIPK1CCNA2CDK2CCNA1
SCHEMBL18366108 0.79 MAPT (0.35) RIPK1ALDH1A1KDM4EHPGDKMT2A
SCHEMBL28404922 0.79 MAPT (0.35) RIPK1ALDH1A1KDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281101-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2025-04-22 US disclosed
EP-3760625-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2024-03-27 EP disclosed
CN-111269221-B Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2023-09-26 CN disclosed
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2022-11-03 US disclosed
EP-3317269-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2022-09-21 EP disclosed
CN-112979660-A Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2021-06-18 CN disclosed
US-10988459-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2021-04-27 US disclosed
CN-107849023-B Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2021-03-23 CN disclosed
EP-3760625-A1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES F. Hoffmann-La Roche AG (CH) 2021-01-06 EP disclosed
CN-111269221-A Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2020-06-12 CN disclosed
WO-2017004500-A9 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-11-30 WO disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 US disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 US disclosed
WO-2017004500-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 RIPK1 3064/4885CCNA2 831/4885CDK2 1641/4885
US-10988459-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 RIPK1 3064/4885CCNA2 831/4885CDK2 1641/4885
US-12281101-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 RIPK1 3064/4885CCNA2 831/4885CDK2 1641/4885
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 RIPK1 3064/4885CCNA2 831/4885CDK2 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.